Publications
2557 results found
Molnar CS, Vida B, Sipos MT, et al., 2012, Morphological Evidence for Enhanced Kisspeptin and Neurokinin B Signaling in the Infundibular Nucleus of the Aging Man, ENDOCRINOLOGY, Vol: 153, Pages: 5428-5439, ISSN: 0013-7227
- Author Web Link
- Cite
- Citations: 31
Hill NE, Murphy KG, Brett S, et al., 2012, CAN THE GASTRIC HORMONE GHRELIN ATTENUATE CATABOLISM AND ENHANCE RECOVERY AND REHABILITATION IN A RODENT MODEL OF ZYMOSAN PERITONITIS?, INTENSIVE CARE MEDICINE, Vol: 38, Pages: S122-S122, ISSN: 0342-4642
Hrabovszky E, Sipos MT, Molnar CS, et al., 2012, Low Degree of Overlap Between Kisspeptin, Neurokinin B, and Dynorphin Immunoreactivities in the Infundibular Nucleus of Young Male Human Subjects Challenges the KNDy Neuron Concept, ENDOCRINOLOGY, Vol: 153, Pages: 4978-4989, ISSN: 0013-7227
- Author Web Link
- Cite
- Citations: 76
Bloom S, 2012, Peptides and obesity, 19th International Symposium on Regulatory Peptides, Publisher: ELSEVIER SCIENCE BV, Pages: S10-S10, ISSN: 0167-0115
Sam AH, Gunner DJ, King A, et al., 2012, Selective Ablation of Peptide YY Cells in Adult Mice Reveals Their Role in Beta Cell Survival, GASTROENTEROLOGY, Vol: 143, Pages: 459-468, ISSN: 0016-5085
- Author Web Link
- Cite
- Citations: 57
Pournaras DJ, Glicksman C, Vincent RP, et al., 2012, The Role of Bile After Roux-en-Y Gastric Bypass in Promoting Weight Loss and Improving Glycaemic Control, ENDOCRINOLOGY, Vol: 153, Pages: 3613-3619, ISSN: 0013-7227
- Author Web Link
- Cite
- Citations: 284
Parker JA, Bloom SR, 2012, Hypothalamic neuropeptides and the regulation of appetite, NEUROPHARMACOLOGY, Vol: 63, Pages: 18-30, ISSN: 0028-3908
- Author Web Link
- Cite
- Citations: 165
Suzuki K, Jayasena CN, Bloom SR, 2012, Obesity and Appetite Control, Experimental Diabetes Research, Vol: 2012, ISSN: 1687-5214
Hankir M, Bueter M, Gsell W, et al., 2012, Increased Energy Expenditure in Gastric Bypass Rats Is Not Caused by Activated Brown Adipose Tissue, OBESITY FACTS, Vol: 5, Pages: 349-358, ISSN: 1662-4025
- Author Web Link
- Cite
- Citations: 18
Ramachandran R, Bech P, Murphy KG, et al., 2012, Improved diagnostic accuracy for neuroendocrine neoplasms using two chromogranin A assays., Clin Endocrinol (Oxf), Vol: 76, Pages: 831-836
Chromogranin A (Cg A) is the best available diagnostic marker for neuroendocrine neoplasms (NENs). However, clinical interpretation of Cg A results may be limited by considerable heterogeneity between commonly available Cg A assays. Variation in diagnostic accuracy of these assays largely reflects differences in antibody specificities. We compared the diagnostic utility of four Cg A assays [Imperial Supra-regional Assay Service radioimmunoassay (SAS) and three commercial assays, Cisbio, DAKO and Eurodiagnostica].
Jayasena CN, Comninos AN, Januszewski A, et al., 2012, Plasma Kisspeptin: A Potential Biomarker of Tumor Metastasis in Patients with Ovarian Carcinoma, CLINICAL CHEMISTRY, Vol: 58, Pages: 1061-1063, ISSN: 0009-9147
- Author Web Link
- Cite
- Citations: 12
Hafeez R, Wagner CV, Smith S, et al., 2012, Patient experiences of MR colonography and colonoscopy: a qualitative study, BRITISH JOURNAL OF RADIOLOGY, Vol: 85, Pages: 765-769, ISSN: 0007-1285
- Author Web Link
- Cite
- Citations: 10
Bech PR, Ramachandran R, Dhillo WS, et al., 2012, Quantifying the Effects of Renal Impairment on Plasma Concentrations of the Neuroendocrine Neoplasia Biomarkers Chromogranin A, Chromogranin B, and Cocaine- and Amphetamine-Regulated Transcript, CLINICAL CHEMISTRY, Vol: 58, Pages: 941-943, ISSN: 0009-9147
- Author Web Link
- Cite
- Citations: 31
Abuirmeileh A, Harkavyi A, Rampersaud N, et al., 2012, Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat, JOURNAL OF PHARMACY AND PHARMACOLOGY, Vol: 64, Pages: 637-643, ISSN: 0022-3573
- Author Web Link
- Cite
- Citations: 24
Fenske WK, Bueter M, Miras AD, et al., 2012, Exogenous peptide YY3-36 and Exendin-4 further decrease food intake, whereas octreotide increases food intake in rats after Roux-en-Y gastric bypass, INTERNATIONAL JOURNAL OF OBESITY, Vol: 36, Pages: 379-384, ISSN: 0307-0565
- Author Web Link
- Cite
- Citations: 42
Cummings DE, Bloom SR, Rubino F, 2012, At the heart of the benefits of bariatric surgery, NATURE MEDICINE, Vol: 18, Pages: 358-359, ISSN: 1078-8956
- Author Web Link
- Cite
- Citations: 1
Jones BJ, Tan T, Bloom SR, 2012, Minireview: Glucagon in Stress and Energy Homeostasis, ENDOCRINOLOGY, Vol: 153, Pages: 1049-1054, ISSN: 0013-7227
- Author Web Link
- Cite
- Citations: 81
Germain N, Galusca B, Feasson L, et al., 2012, Absence of weight gain after 4 weeks of lipidic overnutrition and constitutional thinness: profile of hormines in appetite regulation, DIABETES & METABOLISM, Vol: 38, Pages: A13-A14, ISSN: 1262-3636
Hankir MK, Parkinson JR, Bloom SR, et al., 2012, The effects of glutamate receptor agonists and antagonists on mouse hypothalamic and hippocampal neuronal activity shown through manganese enhanced MRI, NEUROIMAGE, Vol: 59, Pages: 968-978, ISSN: 1053-8119
- Author Web Link
- Cite
- Citations: 17
Ashby D, Choi P, Bloom S, 2012, Ghrelin in cachexia associated with end-stage renal disease, Ghrelin in Health and Disease, Pages: 231-256, ISBN: 9781617799020
Much of the high mortality seen in chronic renal failure is due to a form of vascular disease which, unlike the overnutrition vascular disease of the general population, is closely associated with the development of malnutrition. Various micronutrient de fi ciencies occur, and are commonly treatment related, but a speci fi c syndrome of energy malnutrition associated with unexplained activation of in fl ammatory mediators, is a common and early feature of renal failure, which is frequently refractory to nutritional supplementation. Many abnormalities of appetite hormones have been found in renal failure, and like obesity, renal malnutrition is increasingly understood as a disorder of appetite homeostasis, which therefore would respond best to manipulation of the appetite regulatory system-for example by administration of ghrelin. Reduced clearance by failing kidneys leads to accumulation of ghrelin, with elevated circulating levels of total ghrelin; however, a reduction in the acyl fraction has been found. Acyl ghrelin administration has been shown to increase energy intake in animal models of renal failure, and promising results have also been found with daily subcutaneous injections in dialysis patients over the course of a week. In addition, ghrelin is thought to have an anti-in fl ammatory effect, which may be therapeutically relevant in a syndrome in which inappropriate in fl ammation is a prominent feature.
De Silva A, Bloom SR, 2012, Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity, Gut and Liver, Vol: 6, Pages: 10-20, ISSN: 2005-1212
The global obesity epidemic has resulted in significant morbidity and mortality. However, the medical treatment of obesity is limited. Gastric bypass is an effective surgical treatment but carries signifi cant perioperative risks. The gut hormones, peptide tyrosine tyrosine (PYY) and glucagon-like peptide 1 (GLP-1), are elevated following gastric bypass and have been shown to reduce food intake. They may provide new therapeutic targets. This review article provides an overview of the central control of food intake and the role of PYY and GLP-1 in appetite control. Key translational animal and human studies are reviewed.
Li JV, Ashrafian H, Bueter M, et al., 2012, Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk, Gut, Vol: 60, Pages: 1214-1223
Cetkovic A, Miljic D, Ljubic A, et al., 2012, Plasma Kisspeptin Levels in Pregnancies with Diabetes and Hypertensive Disease as a Potential Marker of Placental Dysfunction and Adverse Perinatal Outcome, ENDOCRINE RESEARCH, Vol: 37, Pages: 78-88, ISSN: 0743-5800
- Author Web Link
- Cite
- Citations: 46
Tan TM, Field BCT, Minnion JS, et al., 2012, Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420., British Journal of Clinical Pharmacology, Vol: 73, Pages: 232-239
AIMS: The objectives of this phase 1 study were to confirm the tolerability ofsingle ascending subcutaneous doses of PP 1420 in healthy subjects, to assess itsadverse effects and to investigate the drug's pharmacokinetics and doseproportionality.METHODS: This was a double-blind, placebo-controlled, randomized study. Therewere three dosing periods. Each subject (n= 12) was randomized to receive onedose of placebo and two ascending doses of PP 1420, given as a subcutaneousinjection. Blood samples were taken over 24 h to assess pharmacokinetics.Standard safety and laboratory data were collected. The primary endpoint was the tolerability of PP 1420. The secondary endpoint was exposure to PP 1420 asassessed by C(max) and AUC(0,∞).RESULTS: PP 1420 was well tolerated by all subjects with no serious adverseeffects. Following single subcutaneous doses of PP 1420 at 2, 4 and 8 mg to male subjects, C(max) was reached at a median t(max) of approximately 1 h post dose(range 0.32-2.00 h). Thereafter, plasma concentrations of PP 1420 declined withgeometric mean apparent terminal elimination t(1/2) ranging from 2.42-2.61 h(range 1.64-3.95 h) across all dose levels.CONCLUSIONS: Subcutaneous PP 1420 was well tolerated in healthy human subjects atsingle doses between 2-8 mg, with no tolerability issues arising. Where observed,adverse events were not serious, and there was no evidence of a dose-relationshipto frequency of adverse events. The results therefore support the conduct ofclinical trials to investigate efficacy, tolerability and pharmacokinetics duringrepeated dosing.
Simpson K, Parker J, Plumer J, et al., 2012, CCK, PYY and PP: the control of energy balance., Handb Exp Pharmacol, Pages: 209-230, ISSN: 0171-2004
The control of food intake consists of neural and hormonal signals between the gut and central nervous system (CNS). Gut hormones such as CCK, PYY and PP signal to important areas in the CNS involved in appetite regulation to terminate a meal. These hormones can act directly via the circulation and activate their respective receptors in the hypothalamus and brainstem. In addition, gut vagal afferents also exist, providing an alternative pathway through which gut hormones can communicate with higher centres through the brainstem. Animal and human studies have demonstrated that peripheral administration of certain gut hormones reduces food intake and leads to weight loss. Gut hormones are therefore potential targets in the development of novel treatments for obesity and analogue therapies are currently under investigation.
Ghourab S, Beale KE, Semjonous NM, et al., 2011, Intracerebroventricular administration of vasoactive intestinal peptide inhibits food intake, REGULATORY PEPTIDES, Vol: 172, Pages: 8-15, ISSN: 0167-0115
- Author Web Link
- Cite
- Citations: 15
Dixon AFR, le Roux CW, Ghatei MA, et al., 2011, Pancreatic Polypeptide Meal Response May Predict Gastric Band-Induced Weight Loss, OBESITY SURGERY, Vol: 21, Pages: 1906-1913, ISSN: 0960-8923
- Author Web Link
- Cite
- Citations: 8
Addison ML, Minnion JS, Shillito JC, et al., 2011, A Role for Metalloendopeptidases in the Breakdown of the Gut Hormone, PYY<sub>3-36</sub>, ENDOCRINOLOGY, Vol: 152, Pages: 4630-4640, ISSN: 0013-7227
- Author Web Link
- Cite
- Citations: 19
Zac-Varghese S, De Silva A, Bloom SR, 2011, Translational studies on PYY as a novel target in obesity, CURRENT OPINION IN PHARMACOLOGY, Vol: 11, Pages: 582-585, ISSN: 1471-4892
- Author Web Link
- Cite
- Citations: 22
Jayasena CN, Nijher GMK, Comninos AN, et al., 2011, The Effects of Kisspeptin-10 on Reproductive Hormone Release Show Sexual Dimorphism in Humans, JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, Vol: 96, Pages: E1963-E1972, ISSN: 0021-972X
- Author Web Link
- Cite
- Citations: 89
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.